Cardiex Ltd (CDX) - Total Assets

Latest as of December 2024: AU$16.99 Million AUD ≈ $12.02 Million USD

Based on the latest financial reports, Cardiex Ltd (CDX) holds total assets worth AU$16.99 Million AUD (≈ $12.02 Million USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See CDX net assets for net asset value and shareholders' equity analysis.

Cardiex Ltd - Total Assets Trend (2002–2024)

This chart illustrates how Cardiex Ltd's total assets have evolved over time, based on quarterly financial data.

Cardiex Ltd - Asset Composition Analysis

Current Asset Composition (June 2024)

Cardiex Ltd's total assets of AU$16.99 Million consist of 82.0% current assets and 18.0% non-current assets.

Asset Category Amount (AUD) % of Total Assets
Cash & Equivalents AU$0.00 3.8%
Accounts Receivable AU$350.99K 2.8%
Inventory AU$2.55 Million 20.2%
Property, Plant & Equipment AU$1.22 Million 9.6%
Intangible Assets AU$619.70K 4.9%
Goodwill AU$0.00 0.0%

Asset Composition Trend (2002–2024)

This chart illustrates how Cardiex Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CDX market cap overview.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Cardiex Ltd's current assets represent 82.0% of total assets in 2024, an increase from 0.0% in 2002.
  • Cash Position: Cash and equivalents constituted 3.8% of total assets in 2024, down from 42.5% in 2002.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 10.0% in 2002.
  • Asset Diversification: The largest asset category is inventory at 20.2% of total assets.

Cardiex Ltd Competitors by Total Assets

Key competitors of Cardiex Ltd based on total assets are shown below.

Company Country Total Assets
Vitrolife AB
ST:VITR
Sweden Skr11.12 Billion
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
China CN¥805.10 Million
Tellgen Corp
SHE:300642
China CN¥2.00 Billion
Lumos Diagnostics Holdings Ltd
AU:LDX
Australia AU$20.81 Million
T&R Biofab Co. Ltd
KQ:246710
Korea ₩83.86 Billion
Ok Biotech Co Ltd
TW:4155
Taiwan NT$3.89 Billion
Promimic AB
ST:PRO
Sweden Skr75.71 Million
Memphasys Ltd
AU:MEM
Australia AU$10.45 Million

Cardiex Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.48 1.02 1.29
Quick Ratio 1.23 0.85 1.22
Cash Ratio 0.00 0.00 0.00
Working Capital AU$4.75 Million AU$321.84K AU$1.05 Million

Cardiex Ltd - Advanced Valuation Insights

This section examines the relationship between Cardiex Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 3.34
Latest Market Cap to Assets Ratio 1.05
Asset Growth Rate (YoY) -11.6%
Total Assets AU$12.65 Million
Market Capitalization $13.23 Million USD

Valuation Analysis

Above Book Valuation: The market values Cardiex Ltd's assets above their book value (1.05x), reflecting positive investor sentiment about the company's future prospects.

Significant Asset Reduction: Cardiex Ltd's assets decreased by 11.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Cardiex Ltd (2002–2024)

The table below shows the annual total assets of Cardiex Ltd from 2002 to 2024.

Year Total Assets Change
2024-06-30 AU$12.65 Million
≈ $8.95 Million
-11.55%
2023-06-30 AU$14.30 Million
≈ $10.12 Million
+15.55%
2022-06-30 AU$12.38 Million
≈ $8.76 Million
+9.89%
2021-06-30 AU$11.26 Million
≈ $7.97 Million
+5.52%
2020-06-30 AU$10.68 Million
≈ $7.55 Million
-19.20%
2019-06-30 AU$13.21 Million
≈ $9.35 Million
+105.99%
2018-06-30 AU$6.41 Million
≈ $4.54 Million
+116.68%
2017-06-30 AU$2.96 Million
≈ $2.09 Million
-35.70%
2016-06-30 AU$4.60 Million
≈ $3.26 Million
-22.68%
2015-06-30 AU$5.95 Million
≈ $4.21 Million
+28.55%
2014-06-30 AU$4.63 Million
≈ $3.28 Million
-27.35%
2013-06-30 AU$6.38 Million
≈ $4.51 Million
+52.45%
2012-06-30 AU$4.18 Million
≈ $2.96 Million
-20.37%
2011-06-30 AU$5.25 Million
≈ $3.72 Million
-11.01%
2010-06-30 AU$5.90 Million
≈ $4.18 Million
-25.30%
2009-06-30 AU$7.90 Million
≈ $5.59 Million
-0.64%
2008-06-30 AU$7.95 Million
≈ $5.63 Million
-30.28%
2007-06-30 AU$11.40 Million
≈ $8.07 Million
-28.03%
2006-06-30 AU$15.85 Million
≈ $11.21 Million
-22.08%
2005-06-30 AU$20.34 Million
≈ $14.39 Million
+518.87%
2004-06-30 AU$3.29 Million
≈ $2.33 Million
+113.10%
2003-06-30 AU$1.54 Million
≈ $1.09 Million
-1.03%
2002-06-30 AU$1.56 Million
≈ $1.10 Million
--

About Cardiex Ltd

AU:CDX Australia Medical Devices
Market Cap
$13.23 Million
AU$18.70 Million AUD
Market Cap Rank
#26156 Global
#1239 in Australia
Share Price
AU$0.03
Change (1 day)
-5.56%
52-Week Range
AU$0.03 - AU$0.06
All Time High
AU$2.74
About

Conneqt Health Limited engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific. It offers SphygmoCor, a vascular biometric technology that captures central hemodynamics and arterial stiffness for noninvasive measurement of vascular biomarkers including central aortic pressures and arterial stiffnes… Read more